Poorly Differentiated and Anaplastic Thyroid Cancer

Patel, Kepal N.; Shaha, Ashok R.

doi:10.1177/107327480601300206

Cited by 183 publications

(143 citation statements)

References 93 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…The proportions observed regarding the histological types are compatible with those described for thyroid carcinoma (16,18,19). We reported 91% of differentiated tumors (83.7% of papillary carcinomas) in contrast with the rate of 72% reported in an epidemiological study of patients from São Paulo (18). However, our sample should not be considered a representation of the population.…”

Section: Discussioncontrasting

confidence: 49%

Surgical treatment for thyroid carcinoma: retrospective study with 811 patients in a Brazilian tertiary hospital

Cavalheiro

Matos

Leite

et al. 2016

Arch. Endocrinol. Metab.

View full text Add to dashboard Cite

Objective: The aim of the present study was to describe the epidemiologic data, histological type, treatment and follow-up of the 811 patients treated for thyroid cancer in Instituto do Câncer do Estado de São Paulo (ICESP) over 5 years. Materials and methods: Retrospective analyses of electronic chart information. Results: There were 679 cases (83.7%) of papillary thyroid cancer, 61 (7.5%) of follicular carcinoma, 54 (6.7%) of medullary carcinoma, 11 (1.4%) of poorly differentiated carcinoma and 6 of anaplastic carcinoma (0.7%). The majority of patients were female (82.2%), and the mean age was 50.5 ± 15 years. Two hundred forty-two patients had disease persistence or recurrence. At the last follow-up, 629 (77.6%) patients were alive and disease free, 141 (17.4%) were alive with disease, and 41 (5.1%) were deceased, with 37 deaths related to thyroid cancer. Conclusion: This study was able to outline the profile, disease type and evolution of patients treated for thyroid cancer at a single tertiary hospital. Arch Endocrinol Metab. 2016;60(5):472-8

show abstract

Section: Discussioncontrasting

confidence: 49%

Surgical treatment for thyroid carcinoma: retrospective study with 811 patients in a Brazilian tertiary hospital

Cavalheiro

Matos

Leite

et al. 2016

Arch. Endocrinol. Metab.

View full text Add to dashboard Cite

show abstract

“…A small subset of these tumors, however, may progress to more aggressive neoplasms such as poorly differentiated and undifferentiated carcinomas. 11,27 Mutations of candidate genes such as TP53 and CTNNB1, the gene encoding b-catenin, and abnormal cell cycle regulation, proliferation, and apoptosis are associated with aggressive neoplasms and have been suggested as markers of thyroid tumor progression. [28][29][30][31][32] Columnar cell carcinoma is a recognized variant of well-differentiated papillary thyroid carcinoma that is associated with an uncertain clinical course.…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma

et al. 2011

View full text Add to dashboard Cite

The majority of papillary thyroid carcinoma is indolent and associated with long-term survival. The columnar cell variant, however, is a rare subtype that is variable in biological behavior; some are clinically aggressive, whereas others are more clinically indolent. Tumor size, tumor circumscription, and encapsulation may influence the behavior of columnar cell carcinomas. Other variables including genetic changes and putative biomarkers associated with malignant growth have not been thoroughly examined in these neoplasms. In this study, nine cases of columnar cell variant of papillary thyroid carcinoma from three institutions were classified as clinically indolent or aggressive based on pathological features, clinical history, and outcome. Indolent tumors were typically small, circumscribed or encapsulated, and from younger female patients, whereas aggressive tumors were large, locally aggressive, associated with regional and distant metastasis, and from older male patients. The missense mutation, V600E in the BRAF oncogene (BRAF V600E ), was detected in three of nine of cases, of which two were clinically aggressive. Immunohistochemical evaluation of neoplasiaassociated markers showed increased nuclear cyclin D1 expression, elevated Ki-67 proliferation indices, and predominantly weak nuclear p53 staining in both indolent and aggressive tumors. Expression of b-catenin was largely restricted to a membranous pattern in both tumor types. Cytoplasmic expression of bcl-2 was overall mildly reduced in indolent neoplasms. Nuclear expression of estrogen and progesterone receptors was increased in both indolent and aggressive neoplasms, but was without sex-or age-related differences; however, whereas progesterone receptor expression was diffuse and strong in clinically indolent carcinomas, its expression was diminished in aggressive neoplasms. Recognition of the clinicopathological characteristics and the molecular and immunophenotypic features of the columnar cell variant of papillary thyroid carcinoma may aid in characterizing neoplasms that behave indolently or aggressively. Keywords: BRAF (BRAF V600E ); b-catenin; columnar cell variant; cyclin D1; papillary thyroid carcinoma Papillary thyroid carcinoma is a common endocrine neoplasm that is typically indolent and associated with long-term survival. This favorable biological behavior reflects the vast majority of conventional and histological variants of well-differentiated papillary thyroid carcinoma. However, a more aggressive tumoral growth characterizes a small subset that behaves more akin to poorly differentiated and undifferentiated thyroid carcinoma. Initially included in this group of aggressive neoplasms, the columnar cell variant is a rare subtype with variable biological behavior. Early reports described tumors with fast growth rates, aggressive local invasion, high rates of recurrence, early metastasis to regional lymph nodes and distant

show abstract

“…Previous studies have shown that WDTC progresses to ATC and PDTC as a result of epithelial-mesenchymal transition (EMT) (Zhong et al 2005, Patel & Shaha 2006, which is accompanied by altered cellular morphology and increased cell spreading (De Craene & Berx 2013). Given the findings of low levels of miR-145 in PDTC and ATC, we postulated that miR-145 may mediate EMT and carried out in vitro studies investigating cellular invasion and migration.…”

Section: Mir-145 Regulates Cellular Invasion and Migration And Emt Mmentioning

confidence: 99%

miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3

Boufraqech¹,

Zhang²,

Jain³

et al. 2014

Endocrine-Related Cancer

View full text Add to dashboard Cite

The expression and function of miR-145 in thyroid cancer is unknown. We evaluated the expression and function of miR-145 in thyroid cancer and its potential clinical application as a biomarker. We found that the expression of miR-145 is significantly downregulated in thyroid cancer as compared with normal. Overexpression of miR-145 in thyroid cancer cell lines resulted in: decreased cell proliferation, migration, invasion, VEGF secretion, and E-cadherin expression. miR-145 overexpression also inhibited the PI3K/Akt pathway and directly targeted AKT3. In vivo, miR-145 overexpression decreased tumor growth and metastasis in a xenograft mouse model, and VEGF secretion. miR-145 inhibition in normal primary follicular thyroid cells decreased the expression of thyroid cell differentiation markers. Analysis of indeterminate fine-needle aspiration samples showed miR-145 had a 92% negative predictive value for distinguishing benign from malignant thyroid nodules. Circulating miR-145 levels were significantly higher in patients with thyroid cancer and showed a venous gradient. Serum exosome extractions revealed that miR-145 is secreted. Our findings suggest that miR-145 is a master regulator of thyroid cancer growth, mediates its effect through the PI3K/Akt pathway, is secreted by the thyroid cancer cells, and may serve as an adjunct biomarker for thyroid cancer diagnosis.

show abstract

Poorly Differentiated and Anaplastic Thyroid Cancer

Cited by 183 publications

References 93 publications

Surgical treatment for thyroid carcinoma: retrospective study with 811 patients in a Brazilian tertiary hospital

Surgical treatment for thyroid carcinoma: retrospective study with 811 patients in a Brazilian tertiary hospital

Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma

miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3

Contact Info

Product

Resources

About